Thirteen Variations of Influenza Vaccines are now Approved for the 2013-14 Influenza Season!

Well Providers its that Influenza time of year again!!   Many of you have already been administering the Influenza Vaccines to your high risk patients.

Don’t forget to update the NDC numbers for each of your vaccines CPT codes before billing.  You will find these on your purchase invoice.  See the table below for the thirteen approved vaccines for the various age levels and types of strains.

 

Name

Manufacturer

Age Range

# of Strains

Afluria

Merck/CSL 9 years and older* Trivalent

Fluarix

GSK 3 years and older Trivalent
Quadrivalent

Flublok

Protein Sciences 18 – 49 years Trivalent

Flucelvax

Novartis 18 years and older Trivalent

FluLaval

GSK 3 years and older Trivalent
Quadrivalent

FluMist

Medimmune 2 – 49 years Quadrivalent

Fluvirin

Novartis 4 years and older Trivalent

Fluzone

Sanofi Pasteur 6 months and older Trivalent
Quadrivalent

Fluzone High-Dose

Sanofi Pasteur 65 years and older Trivalent

Fluzone Intradermal

Sanofi Pasteur 18 – 64 years Trivalent

Influenza Virus Strains in the 2013-2014 Vaccines

  • A/California/7/2009 (H1N1)-like
  • A/Victoria/361/2011 (H3N2), or its antigenic equivalent
  • B/Massachusetts/2/2012-like (Yamagata lineage)

Quadrivalent formulations will also include
B/Brisbane/60/2008-like (Victoria lineage)

Abbreviations used for influenza vaccines

  • IIV: Inactivated Influenza Vaccine (Afluria, Fluarix, FluLaval, Fluvirin, Fluzone)
    (IIV3 = Trivalent IIV; IIV4 = Quadrivalent IIV)
  • LAIV (Quadrivalent): Live, Attenuated Influenza Vaccine (FluMist)
  • RIV3: Recombinant Influenza Vaccine, Trivalent (Flublok)
  • ccIIV3: Cell Culture Inactivated Influenza Vaccine, Trivalent (Flucelvax)

Concurrent Administration

Influenza vaccines may be administered concurrently with other live or inactivated vaccines.

As always “Take Advantage” for all of your billing and practice software needs.  Phone 877.666.5279

SIGNATURE

Comments

  1. says

    I blog frequently and I truly thank you
    for your content. This article has really peaked my interest.
    I will take a note of your website and keep checking for new information about once per week.
    I opted in for your Feed as well.

Leave a Reply

Your email address will not be published. Required fields are marked *